FDA Inspection 1236867 — Bristol-Myers Squibb Company
The FDA completed an inspection of Bristol-Myers Squibb Company on Apr 24, 2024 in Princeton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Apr 24, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Princeton, NJ (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)